Dilated cardiomyopathy

[1]  K. Stergiopoulos,et al.  Peripartum cardiomyopathy-diagnosis, management, and long term implications. , 2019, Trends in cardiovascular medicine.

[2]  C. Caleshu,et al.  Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes , 2019, Circulation. Genomic and precision medicine.

[3]  M. Ieda,et al.  Progress and Challenge of Cardiac Regeneration to Treat Heart Failure. , 2019, Journal of cardiology.

[4]  L. Cooper,et al.  Elevated Sera sST2 Is Associated With Heart Failure in Men ≤50 Years Old With Myocarditis , 2019, Journal of the American Heart Association.

[5]  J. Downey,et al.  Circulating blood cells and extracellular vesicles in acute cardioprotection. , 2018, Cardiovascular research.

[6]  P. Hantson.  Mechanisms of toxic cardiomyopathy , 2018, Clinical toxicology.

[7]  M. Javadi,et al.  Longitudinal 18F-FDG PET imaging in a rat model of autoimmune myocarditis , 2018, European heart journal cardiovascular Imaging.

[8]  J. MacInnes,et al.  A review of integrated heart failure care , 2018, Primary Health Care Research & Development.

[9]  P. Pellikka,et al.  Echocardiographic Assessment of Left Ventricular Systolic Function: An Overview of Contemporary Techniques, Including Speckle‐Tracking Echocardiography , 2019, Mayo Clinic proceedings.

[10]  M. Dorobanțu,et al.  The Winding Road of Cardiac Regeneration—Stem Cell Omics in the Spotlight , 2018, Cells.

[11]  T. Edvardsen,et al.  Echocardiographic assessment of left ventricular systolic function , 2018, Journal of Echocardiography.

[12]  E. Arbustini,et al.  Cardiac Phenotypes in Hereditary Muscle Disorders: JACC State-of-the-Art Review. , 2018, Journal of the American College of Cardiology.

[13]  D. Pennell,et al.  Sex‐ and age‐based differences in the natural history and outcome of dilated cardiomyopathy , 2018, European journal of heart failure.

[14]  G. Barbati,et al.  Arrhythmic Risk Stratification in Patients With Idiopathic Dilated Cardiomyopathy. , 2018, The American journal of cardiology.

[15]  D. O’Regan,et al.  Genetic Etiology for Alcohol-Induced Cardiac Toxicity , 2018, Journal of the American College of Cardiology.

[16]  P. Lancellotti,et al.  [Update on myocarditis]. , 2018, Revue medicale de Liege.

[17]  S. Cook,et al.  Role of titin in cardiomyopathy: from DNA variants to patient stratification , 2018, Nature Reviews Cardiology.

[18]  S. Heymans,et al.  Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias , 2018, European heart journal.

[19]  A. Kaider,et al.  GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2 , 2018, Journal of cellular and molecular medicine.

[20]  Kenneth L. Jones,et al.  Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell–Cell Adhesion Structures , 2018, JACC. Clinical electrophysiology.

[21]  P. Elliott,et al.  Evolving concepts in dilated cardiomyopathy , 2018, European journal of heart failure.

[22]  V. Ruppert,et al.  The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure , 2018, Open Heart.

[23]  N. Nair,et al.  Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy , 2018, Journal of circulating biomarkers.

[24]  M. Giacca,et al.  The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC , 2018, European journal of heart failure.

[25]  Kaviyarasi Renu,et al.  Molecular mechanism of doxorubicin‐induced cardiomyopathy – An update , 2018, European journal of pharmacology.

[26]  C. Jung,et al.  Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure , 2017, Acta Pharmacologica Sinica.

[27]  V. Betihavas,et al.  The effect of nurse-led education on hospitalisation, readmission, quality of life and cost in adults with heart failure. A systematic review. , 2017, Patient education and counseling.

[28]  P. Gonzalez-Alegre,et al.  Towards precision medicine , 2017 .

[29]  W. Shimizu,et al.  Gene-Based Risk Stratification for Cardiac Disorders in LMNA Mutation Carriers , 2017, Circulation. Cardiovascular genetics.

[30]  D. Nickerson,et al.  Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy: Design and Implementation of the DCM Precision Medicine Study , 2017, Circulation. Cardiovascular genetics.

[31]  M. Mussap,et al.  Free light chains: Eclectic multipurpose biomarker. , 2017, Journal of immunological methods.

[32]  V. Falk,et al.  Myocardial Regeneration via Progenitor Cell-Derived Exosomes , 2017, Stem cells international.

[33]  R. Francis,et al.  Myocardial biopsy: techniques and indications , 2017, Heart.

[34]  C. Schernthaner,et al.  A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. , 2017, European journal of internal medicine.

[35]  B. Pieske,et al.  Multimodality imaging approach in the diagnosis of chronic myocarditis with preserved left ventricular ejection fraction (MCpEF): The role of 2D speckle-tracking echocardiography. , 2017, International journal of cardiology.

[36]  L. Mestroni,et al.  Dilated Cardiomyopathy: Genetic Determinants and Mechanisms , 2017, Circulation research.

[37]  E. Braunwald.  Cardiomyopathies: An Overview. , 2017, Circulation research.

[38]  B. Maron,et al.  Classification, Epidemiology, and Global Burden of Cardiomyopathies. , 2017, Circulation research.

[39]  A. Tajik,et al.  Modern Imaging Techniques in Cardiomyopathies. , 2017, Circulation research.

[40]  U. Eriksson,et al.  Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease , 2017, European heart journal.

[41]  S. Pinkert,et al.  NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis , 2017, Circulation. Heart failure.

[42]  K. Sliwa,et al.  Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study , 2017, European heart journal.

[43]  P. M. van de Ven,et al.  Usefulness of Left Atrial Emptying Fraction to Predict Ventricular Arrhythmias in Patients With Implantable Cardioverter Defibrillators. , 2017, The American journal of cardiology.

[44]  J. Cleland,et al.  Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future , 2017, Circulation.

[45]  R. Kloner,et al.  The Cardiovascular Effects of Cocaine. , 2017, Journal of the American College of Cardiology.

[46]  D. Valle,et al.  LMNA Sequences of 60,706 Unrelated Individuals Reveal 132 Novel Missense Variants in A-Type Lamins and Suggest a Link between Variant p.G602S and Type 2 Diabetes , 2017, Front. Genet..

[47]  J. Michael Cherry,et al.  Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource , 2017, bioRxiv.

[48]  J. Rehm,et al.  Quantifying the global contribution of alcohol consumption to cardiomyopathy , 2017, Population Health Metrics.

[49]  L. Mestroni,et al.  Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy , 2017, Heart.

[50]  J. Casanova,et al.  Autosomal Recessive Cardiomyopathy Presenting as Acute Myocarditis. , 2017, Journal of the American College of Cardiology.

[51]  K. Knowlton.  Myocarditis: An Intersection Between Genetic and Acquired Causes of Human Cardiomyopathy. , 2017, Journal of the American College of Cardiology.

[52]  I. Coppens,et al.  Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy , 2017, The Journal of experimental medicine.

[53]  Y. Pinto,et al.  Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy , 2017, European journal of heart failure.

[54]  H. Katus,et al.  A Distinct Cardiomyopathy: HCN4 Syndrome Comprising Myocardial Noncompaction, Bradycardia, Mitral Valve Defects, and Aortic Dilation. , 2017, Journal of the American College of Cardiology.

[55]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[56]  J. Michael Cherry,et al.  Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource , 2017, bioRxiv.

[57]  C. Muñoz-Almagro,et al.  Molecular epidemiology of enterovirus and parechovirus infections according to patient age over a 4‐year period in Spain , 2017, Journal of medical virology.

[58]  W. Chung,et al.  Differences in Presentation and Outcomes Between Children With Familial Dilated Cardiomyopathy and Children With Idiopathic Dilated Cardiomyopathy: A Report From the Pediatric Cardiomyopathy Registry Study Group , 2017, Circulation. Heart failure.

[59]  R. Hendel,et al.  Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. , 2017, Journal of the American College of Cardiology.

[60]  S. Cook,et al.  Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes , 2017, European heart journal.

[61]  P. Arora,et al.  Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis. , 2017, Circulation.

[62]  Daniel Rueckert,et al.  Titin truncating variants affect heart function in disease cohorts and the general population , 2016, Nature Genetics.

[63]  D. MacArthur,et al.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.

[64]  James A. White,et al.  Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. , 2017, JACC. Heart failure.

[65]  W. Kraus,et al.  Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure , 2017 .

[66]  Georgios Kararigas,et al.  Mechanistic Pathways of Sex Differences in Cardiovascular Disease. , 2017, Physiological reviews.

[67]  M. Zilliox,et al.  Cardiac inflammation in genetic dilated cardiomyopathy caused by MYBPC3 mutation. , 2017, Journal of molecular and cellular cardiology.

[68]  L. Calò,et al.  Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. , 2016, Journal of the American College of Cardiology.

[69]  W. Stevenson,et al.  Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. , 2016, Journal of the American College of Cardiology.

[70]  M. Stavrou,et al.  Diagnosis of Dilated Cardiomyopathy: Patient Reaction and Adaptation—Case Study and Review of the Literature , 2016, Case reports in psychiatry.

[71]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[72]  Ashutosh Kumar Singh,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[73]  L. Mestroni,et al.  Early Arrhythmic Events in Idiopathic Dilated Cardiomyopathy. , 2016, JACC. Clinical electrophysiology.

[74]  A. Pagnamenta,et al.  Combination of Whole Genome Sequencing, Linkage, and Functional Studies Implicates a Missense Mutation in Titin as a Cause of Autosomal Dominant Cardiomyopathy With Features of Left Ventricular Noncompaction , 2016, Circulation. Cardiovascular genetics.

[75]  Characterization and Long-Term Prognosis of Postmyocarditic Dilated Cardiomyopathy Compared With Idiopathic Dilated Cardiomyopathy. , 2016, The American journal of cardiology.

[76]  J. Bartunek,et al.  Myocarditis in Clinical Practice. , 2016, Mayo Clinic proceedings.

[77]  Marco Merlo,et al.  The Prognostic Impact of the Evolution of RV Function in Idiopathic DCM. , 2016, JACC. Cardiovascular imaging.

[78]  J. Seidman,et al.  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.

[79]  E. Ashley.  Towards precision medicine , 2016, Nature Reviews Genetics.

[80]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[81]  J. Shendure.  Human genomics: A deep dive into genetic variation , 2016, Nature.

[82]  Kenneth L. Jones,et al.  FLNC Gene Splice Mutations Cause Dilated Cardiomyopathy , 2016, JACC. Basic to translational science.

[83]  S. Cook,et al.  The Diagnosis and Evaluation of Dilated Cardiomyopathy. , 2016, Journal of the American College of Cardiology.

[84]  L. Cooper,et al.  Cardiac myosin-Th17 responses promote heart failure in human myocarditis. , 2016, JCI insight.

[85]  B. Pieske,et al.  Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy , 2016, Clinical Research in Cardiology.

[86]  S. Heymans,et al.  Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. , 2016, European heart journal.

[87]  S. Holmberg,et al.  Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  J. McMurray,et al.  The incremental prognostic and clinical value of multiple novel biomarkers in heart failure , 2016, European journal of heart failure.

[89]  E. Arbustini,et al.  Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy , 2016, Clinical Research in Cardiology.

[90]  G. Carvill,et al.  Pitfalls in genetic testing: the story of missed SCN1A mutations , 2016, Molecular genetics & genomic medicine.

[91]  B. Brembilla-Perrot,et al.  Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation , 2016, European journal of heart failure.

[92]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[93]  A. Maisel,et al.  Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure , 2016, Arquivos brasileiros de cardiologia.

[94]  T. Nakata,et al.  Prognostic Value of Cardiac Sympathetic Nerve Imaging Using Long-Term Follow-up Data - Ischemic vs. Non-Ischemic Heart Failure Etiology. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[95]  J. Seidman,et al.  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.

[96]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[97]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[98]  J. Hamako,et al.  von Willebrand factor and von Willebrand disease. , 2016, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[99]  M. Nishimura,et al.  F-fluorodeoxyglucose Positron Emission Tomography (fdg Pet) and Cardiac Magnetic Resonance (cmr) in Corticosteroid-naive Patients with Conduction System Disease Due to Cardiac Sarcoidosis , 2022 .

[100]  Carlos L Arteaga,et al.  Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. , 2015, Circulation.

[101]  M. Giacca,et al.  Harnessing the microRNA pathway for cardiac regeneration. , 2015, Journal of molecular and cellular cardiology.

[102]  R. Hershberger,et al.  The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy. , 2015, The Canadian journal of cardiology.

[103]  V. Fuster,et al.  Viral myocarditis—diagnosis, treatment options, and current controversies , 2015, Nature Reviews Cardiology.

[104]  P. Ferdinandy,et al.  Drug-induced mitochondrial dysfunction and cardiotoxicity. , 2015, American journal of physiology. Heart and circulatory physiology.

[105]  Kenneth L. Jones,et al.  Role of Titin Missense Variants in Dilated Cardiomyopathy , 2015, Journal of the American Heart Association.

[106]  A. Moss,et al.  Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients: Data From the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry) , 2015, Circulation.

[107]  L. Mestroni,et al.  Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Life‐Threatening Arrhythmias , 2015, Journal of the American Heart Association.

[108]  R. Hershberger,et al.  Dilated Cardiomyopathy Overview , 2015 .

[109]  S. Heymans,et al.  Prognostic Relevance of Gene-Environment Interactions in Patients With Dilated Cardiomyopathy: Applying the MOGE(S) Classification. , 2015, Journal of the American College of Cardiology.

[110]  Yucheng Chen,et al.  Prognostic value of late gadolinium enhancement in dilated cardiomyopathy patients: a meta-analysis. , 2015, Clinical radiology.

[111]  J. McMurray,et al.  Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. , 2015, JACC. Heart failure.

[112]  L. Zentilin,et al.  Intracoronary Cytoprotective Gene Therapy: A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[113]  R. Hershberger,et al.  A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia. , 2015, Cardiovascular research.

[114]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[115]  U. Kramer,et al.  Clinical and Histopathological Features of Patients with Systemic Sclerosis Undergoing Endomyocardial Biopsy , 2015, PloS one.

[116]  Emily K. Tsang,et al.  Effect of predicted protein-truncating genetic variants on the human transcriptome , 2015, Science.

[117]  J. Seidman,et al.  Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain , 2015, Heart.

[118]  M. Mokry,et al.  A systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscle‐specific genes , 2015, European journal of heart failure.

[119]  J. Cheung,et al.  BAG3: a new player in the heart failure paradigm , 2015, Heart Failure Reviews.

[120]  Reza Razavi,et al.  Myocardial tissue characterization by cardiac magnetic resonance imaging using T1 mapping predicts ventricular arrhythmia in ischemic and non-ischemic cardiomyopathy patients with implantable cardioverter-defibrillators. , 2015, Heart rhythm.

[121]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[122]  Yiyi Zhang,et al.  Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients. , 2015, Heart rhythm.

[123]  D. Mann,et al.  Role of innate and adaptive immune mechanisms in cardiac injury and repair , 2015, Nature Reviews Immunology.

[124]  A. Angelini,et al.  Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. , 2015, International journal of cardiology.

[125]  Tan Ru San,et al.  Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease , 2015, Science Translational Medicine.

[126]  A. Fulton,et al.  Panel-based Genetic Diagnostic Testing for Inherited Eye Diseases is Highly Accurate and Reproducible and More Sensitive for Variant Detection Than Exome Sequencing , 2014, Genetics in Medicine.

[127]  F. Domínguez,et al.  Natural history and prognostic factors in alcoholic cardiomyopathy. , 2015, JACC. Heart failure.

[128]  W. Hoffmann,et al.  Analysis of endomyocardial biopsies in suspected myocarditis--diagnostic value of left versus right ventricular biopsy. , 2014, International journal of cardiology.

[129]  X. Puente,et al.  Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy , 2014, Nature Communications.

[130]  C. Tschöpe,et al.  Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome , 2014, European journal of heart failure.

[131]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[132]  C. Tschöpe,et al.  Improved diagnosis of idiopathic giant cell myocarditis and cardiac sarcoidosis by myocardial gene expression profiling. , 2014, European heart journal.

[133]  R. Hauer,et al.  Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study , 2014, Circulation. Cardiovascular genetics.

[134]  N. Rajewsky,et al.  RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. , 2014, The Journal of clinical investigation.

[135]  V. Fuster,et al.  The MOGE(S) classification of cardiomyopathy for clinicians. , 2014, Journal of the American College of Cardiology.

[136]  Amit R. Patel,et al.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.

[137]  M. Pasotti.  The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: more questions than answers? , 2014, Journal of the American College of Cardiology.

[138]  A. Kadish,et al.  Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. , 2014, Journal of the American College of Cardiology.

[139]  Benjamin Meder,et al.  A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. , 2014, European heart journal.

[140]  Feng Liu,et al.  Impact of Etiology on the Outcomes in Heart Failure Patients Treated with Cardiac Resynchronization Therapy: A Meta-Analysis , 2014, PloS one.

[141]  Nai-Wan Hsiao,et al.  Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients , 2014, Hepatology.

[142]  Marco Merlo,et al.  Long‐term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years , 2014, European journal of heart failure.

[143]  F. Villarreal,et al.  Dynamic Changes in Myocardial Matrix and Relevance to Disease: Translational Perspectives , 2014, Circulation research.

[144]  T. Guilarte,et al.  Sex Differences in Translocator Protein 18 kDa (TSPO) in the Heart: Implications for Imaging Myocardial Inflammation , 2014, Journal of Cardiovascular Translational Research.

[145]  G. W. Dec,et al.  The natural history of acute dilated cardiomyopathy. , 2014, Transactions of the American Clinical and Climatological Association.

[146]  J. Seidman,et al.  Genetics and disease of ventricular muscle. , 2014, Cold Spring Harbor perspectives in medicine.

[147]  J. Baugh,et al.  Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target , 2014, Heart Failure Reviews.

[148]  V. Fuster,et al.  The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. , 2013, Journal of the American College of Cardiology.

[149]  L. Mestroni,et al.  Poor Prognosis of Rare Sarcomeric Gene Variants in Patients with Dilated Cardiomyopathy , 2013, Clinical and translational science.

[150]  J. Wilkinson,et al.  Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. , 2013, Future cardiology.

[151]  Tevfik F Ismail,et al.  The Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Nonischemic Dilated Cardiomyopathy , 2013, Circulation.

[152]  A. Frustaci,et al.  Contribution and Risks of Left Ventricular Endomyocardial Biopsy in Patients With Cardiomyopathies: A Retrospective Study Over a 28-Year Period , 2013, Circulation.

[153]  D. Hedges,et al.  Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.

[154]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[155]  K. Zwierz,et al.  Binge drinking-induced subtle myocardial injury. , 2013, Alcoholism, clinical and experimental research.

[156]  A. Matsumori,et al.  Dilated cardiomyopathy update: infectious-immune theory revisited , 2013, Heart Failure Reviews.

[157]  G. Gensini,et al.  Improving Survival Rates of Patients With Idiopathic Dilated Cardiomyopathy in Tuscany Over 3 Decades: Impact of Evidence-Based Management , 2013, Circulation. Heart failure.

[158]  J. Xie,et al.  Prognostic value of late gadolinium enhancement in dilated cardiomyopathy patients. A meta-analysis. , 2013, Saudi medical journal.

[159]  S. Russell,et al.  Evaluation of the Role of Endomyocardial Biopsy in 851 Patients With Unexplained Heart Failure From 2000–2009 , 2013, Circulation. Heart failure.

[160]  Y. Pinto,et al.  Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[161]  A. Zwinderman,et al.  Gender‐specific differences in major cardiac events and mortality in lamin A/C mutation carriers , 2013, European journal of heart failure.

[162]  Niklas Krumm,et al.  Exome Sequencing and Genome-Wide Linkage Analysis in 17 Families Illustrate the Complex Contribution of TTN Truncating Variants to Dilated Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.

[163]  Tevfik F Ismail,et al.  Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.

[164]  E. McNally,et al.  Genetic mutations and mechanisms in dilated cardiomyopathy. , 2013, The Journal of clinical investigation.

[165]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[166]  S. H. Mehani,et al.  Correlation between changes in diastolic dysfunction and health-related quality of life after cardiac rehabilitation program in dilated cardiomyopathy , 2012, Journal of advanced research.

[167]  B. Carter.  2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology , 2013 .

[168]  L. Cooper,et al.  Sex and gender differences in myocarditis and dilated cardiomyopathy. , 2013, Current problems in cardiology.

[169]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[170]  R. Hauer,et al.  Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy , 2012, European journal of heart failure.

[171]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[172]  H. Schultheiss,et al.  Interferon-Beta improves survival in enterovirus-associated cardiomyopathy. , 2012, Journal of the American College of Cardiology.

[173]  S. Colan,et al.  Subtle Abnormalities in Contractile Function Are an Early Manifestation of Sarcomere Mutations in Dilated Cardiomyopathy , 2012, Circulation. Cardiovascular genetics.

[174]  R. Hershberger,et al.  Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure. , 2012, Journal of the American College of Cardiology.

[175]  T. Therneau,et al.  Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. , 2012, Mayo Clinic proceedings.

[176]  T. Edvardsen,et al.  Risk assessment of ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy by strain echocardiography. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[177]  W. Mitzner,et al.  IL-33 Independently Induces Eosinophilic Pericarditis and Cardiac Dilation: ST2 Improves Cardiac Function , 2012, Circulation. Heart failure.

[178]  W. Mitzner,et al.  Testosterone and interleukin-1β increase cardiac remodeling during coxsackievirus B3 myocarditis via serpin A 3n. , 2012, American journal of physiology. Heart and circulatory physiology.

[179]  G. Derumeaux,et al.  Diabetic cardiomyopathy: myth or reality? , 2012, Archives of cardiovascular diseases.

[180]  Sandeep Sagar,et al.  Myocarditis , 2012, The Lancet.

[181]  G. Barbati,et al.  How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?". , 2012, The American journal of cardiology.

[182]  M. Mcgoon,et al.  REVEAL: a contemporary US pulmonary arterial hypertension registry , 2012, European Respiratory Review.

[183]  P. Ellinor,et al.  Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. , 2012, Heart rhythm.

[184]  L. Mestroni,et al.  Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.

[185]  W. McKenna,et al.  Genetics of inherited cardiomyopathy. , 2012, European heart journal.

[186]  Farshid S. Garmaroudi,et al.  Inflammation in Myocardial Diseases , 2012, Circulation research.

[187]  Ziya Kaya,et al.  Autoantibodies in heart failure and cardiac dysfunction. , 2012, Circulation research.

[188]  Michael J. Becich,et al.  Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics , 2012, Journal of pathology informatics.

[189]  L. Cooper,et al.  Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. , 2012, Journal of cardiac failure.

[190]  T. Arimura,et al.  Dilated cardiomyopathy‐associated BAG3 mutations impair Z‐disc assembly and enhance sensitivity to apoptosis in cardiomyocytes , 2011, Human mutation.

[191]  Mike Kirby,et al.  Guidelines on the management of cardiovascular diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology ( ESC ) , 2011 .

[192]  L. Cooper,et al.  The management of myocarditis. , 2011, European heart journal.

[193]  A. Matsumori,et al.  Assessment of cardiac involvement of hepatitis C virus; tissue Doppler imaging and NTproBNP study. , 2011, Journal of the Saudi Heart Association.

[194]  L. Cooper,et al.  Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. , 2011, Journal of the American College of Cardiology.

[195]  Q. Wells,et al.  Familial dilated cardiomyopathy associated with congenital defects in the setting of a novel VCL mutation (Lys815Arg) in conjunction with a known MYPBC3 variant. , 2011, Cardiogenetics.

[196]  S. Colan,et al.  Competing Risks for Death and Cardiac Transplantation in Children With Dilated Cardiomyopathy: Results From the Pediatric Cardiomyopathy Registry , 2011, Circulation.

[197]  N. Norton,et al.  Functional Characterization of TNNC1 Rare Variants Identified in Dilated Cardiomyopathy* , 2011, The Journal of Biological Chemistry.

[198]  C. Hayward,et al.  Evaluation of Left Ventricular Enlargement as a Marker of Early Disease in Familial Dilated Cardiomyopathy , 2011, Circulation. Cardiovascular genetics.

[199]  Bernard P. Puc,et al.  An integrated semiconductor device enabling non-optical genome sequencing , 2011, Nature.

[200]  H. Volk,et al.  Expression of functional T‐cell markers and T‐cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy , 2011, European journal of heart failure.

[201]  J. Caldwell,et al.  SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. , 2011, Journal of the American College of Cardiology.

[202]  R. Hershberger,et al.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. , 2011, Journal of the American College of Cardiology.

[203]  Marco Merlo,et al.  Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. , 2011, Journal of the American College of Cardiology.

[204]  Deborah A Nickerson,et al.  Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. , 2011, American journal of human genetics.

[205]  A. Matsumori,et al.  The biomarker N-terminal pro-brain natriuretic peptide and liver diseases. , 2011, Clinical and investigative medicine. Medecine clinique et experimentale.

[206]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[207]  Sana M. Al-Khatib,et al.  Non-evidence-based ICD implantations in the United States. , 2011, JAMA.

[208]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[209]  Ana Morales,et al.  Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals , 2010, Genetics in Medicine.

[210]  D. Corrado,et al.  Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia , 2010, Heart.

[211]  W. McKenna,et al.  The Cardiac Desmosome and Arrhythmogenic Cardiomyopathies: From Gene to Disease , 2010, Circulation research.

[212]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[213]  L. Mestroni,et al.  Prognostic impact of familial screening in dilated cardiomyopathy , 2010, European journal of heart failure.

[214]  M. Schieber,et al.  Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy: Differences in Complication Rate and Diagnostic Performance , 2010, Circulation.

[215]  J. Chambers,et al.  Mutational Heterogeneity, Modifier Genes, and Environmental Influences Contribute to Phenotypic Diversity of Arrhythmogenic Cardiomyopathy , 2010, Circulation. Cardiovascular genetics.

[216]  M. Sheppard,et al.  Prevalence of Desmosomal Protein Gene Mutations in Patients With Dilated Cardiomyopathy , 2010, Circulation. Cardiovascular genetics.

[217]  N. Norton,et al.  Identification of Novel Mutations in RBM20 in Patients with Dilated Cardiomyopathy , 2010, Clinical and translational science.

[218]  A. Gomes,et al.  Mutations in Troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function? , 2010, Journal of molecular and cellular cardiology.

[219]  N. Norton,et al.  Coding Sequence Rare Variants Identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 From 312 Patients With Familial or Idiopathic Dilated Cardiomyopathy , 2010, Circulation. Cardiovascular genetics.

[220]  Y. Iwakura,et al.  Interleukin-17A Is Dispensable for Myocarditis but Essential for the Progression to Dilated Cardiomyopathy , 2010, Circulation research.

[221]  S. Lipshultz,et al.  Cardiotoxicity after childhood cancer: beginning with the end in mind. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[222]  Birgit Funke,et al.  Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[223]  M. Cheitlin.  Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study , 2010 .

[224]  A. Acha-Sagredo,et al.  Oral cancer and polymorphism of ethanol metabolising genes. , 2010, Oral oncology.

[225]  Norman Honbo,et al.  Doxorubicin Cardiomyopathy , 2009, Cardiology.

[226]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[227]  Juan Cinca,et al.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. , 2009, Journal of the American College of Cardiology.

[228]  P. Pellikka,et al.  Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[229]  M. Friedrich,et al.  Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study , 2009, Heart.

[230]  D. Fatkin,et al.  Identification and Functional Characterization of Cardiac Troponin I As a Novel Disease Gene in Autosomal Dominant Dilated Cardiomyopathy , 2009, Circulation research.

[231]  G. Rosano,et al.  Gender differences in the cardiovascular effect of sex hormones , 2009, Nature Reviews Cardiology.

[232]  J. Potter,et al.  Clinical and Functional Characterization of TNNT2 Mutations Identified in Patients With Dilated Cardiomyopathy , 2009, Circulation. Cardiovascular genetics.

[233]  Andrea Frustaci,et al.  Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. , 2009, European heart journal.

[234]  S. Klein,et al.  Gonadectomy of male BALB/c mice increases Tim-3+ alternatively activated M2 macrophages, Tim-3+ T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis , 2009, Brain, Behavior, and Immunity.

[235]  W. Kraus,et al.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[236]  P. Ponikowski,et al.  Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology , 2009, European journal of heart failure.

[237]  C. Schneider,et al.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. , 2008, European heart journal.

[238]  M. Viitasalo,et al.  Search for cardiac calcium cycling gene mutations in familial ventricular arrhythmias resembling catecholaminergic polymorphic ventricular tachycardia , 2009, BMC Medical Genetics.

[239]  Dudley J Pennell,et al.  Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. , 2008, Journal of the American College of Cardiology.

[240]  W. Giles,et al.  Cardiac troponin T mutations promote life-threatening arrhythmias. , 2008, The Journal of clinical investigation.

[241]  S. Réhman,et al.  Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. , 2008, Journal of the American College of Cardiology.

[242]  W. Hoffmann,et al.  Complication Rate of Right Ventricular Endomyocardial Biopsy via the Femoral Approach: A Retrospective and Prospective Study Analyzing 3048 Diagnostic Procedures Over an 11-Year Period , 2008, Circulation.

[243]  T. Kubo,et al.  Improvement in prognosis of dilated cardiomyopathy in the elderly over the past 20 years. , 2008, Journal of cardiology.

[244]  Michael Böhm,et al.  Predictors of Outcome in Patients With Suspected Myocarditis , 2008, Circulation.

[245]  Margaret L. Karst,et al.  Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology , 2008, Clinical genetics.

[246]  S. Heymans,et al.  Acute viral myocarditis , 2008, European heart journal.

[247]  P. Rahko,et al.  Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. , 2008, American heart journal.

[248]  P. Ponikowski,et al.  Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II , 2008, European journal of heart failure.

[249]  S. Iliceto,et al.  Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy , 2008, Autoimmunity.

[250]  Eloisa Arbustini,et al.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.

[251]  M. Cheitlin.  Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial , 2008 .

[252]  P. Binkley,et al.  Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event. , 2008, American heart journal.

[253]  Renu Virmani,et al.  A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology , 2022 .

[254]  L. Fauchier,et al.  Comparison of the beneficial effect of beta‐blockers on mortality in patients with ischaemic or non‐ischaemic systolic heart failure: A meta‐analysis of randomised controlled trials , 2007, European journal of heart failure.

[255]  C. Angermann,et al.  A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. , 2007, Journal of the American College of Cardiology.

[256]  D. Mozaffarian,et al.  Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model , 2007, Circulation.

[257]  N. Rose,et al.  Cutting Edge: Cross-Regulation by TLR4 and T cell Ig Mucin-3 Determines Sex Differences in Inflammatory Heart Disease1 , 2007, The Journal of Immunology.

[258]  A. Angelini,et al.  A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. , 2007, European heart journal.

[259]  Anne L. Taylor,et al.  Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial , 2007, Circulation.

[260]  C. Long,et al.  Prevalence of Desmin Mutations in Dilated Cardiomyopathy , 2007, Circulation.

[261]  Peter P. Liu,et al.  Connecting the missing link between dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton, and innate immunity. , 2006, Circulation.

[262]  P. Elliott,et al.  Prospective Familial Assessment in Dilated Cardiomyopathy: Cardiac Autoantibodies Predict Disease Development in Asymptomatic Relatives , 2006, Circulation.

[263]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[264]  Stanley D. Kosanke,et al.  Mimicry and Antibody-Mediated Cell Signaling in Autoimmune Myocarditis1 , 2006, The Journal of Immunology.

[265]  S. Colan,et al.  Incidence, causes, and outcomes of dilated cardiomyopathy in children. , 2006, JAMA.

[266]  B. Soliven,et al.  Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[267]  Nick Freemantle,et al.  Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. , 2006, European heart journal.

[268]  John Atherton,et al.  Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy , 2006, Journal of Molecular Medicine.

[269]  J. Mason,et al.  Myocarditis and heart failure associated with hepatitis C virus infection. , 2006, Journal of cardiac failure.

[270]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[271]  Ziya Kaya,et al.  Complement Receptor 1 and 2 Deficiency Increases Coxsackievirus B3-Induced Myocarditis, Dilated Cardiomyopathy, and Heart Failure by Increasing Macrophages, IL-1β, and Immune Complex Deposition in the Heart1 , 2006, The Journal of Immunology.

[272]  Jared W. Magnani,et al.  Myocarditis: Current Trends in Diagnosis and Treatment , 2006, Circulation.

[273]  J. Belmont,et al.  Genetic Predictors and Remodeling of Dilated Cardiomyopathy in Muscular Dystrophy , 2005, Circulation.

[274]  S. Akira,et al.  Myeloid Differentiation Factor-88 Plays a Crucial Role in the Pathogenesis of Coxsackievirus B3–Induced Myocarditis and Influences Type I Interferon Production , 2005, Circulation.

[275]  H. Schultheiss,et al.  Viral Persistence in the Myocardium Is Associated With Progressive Cardiac Dysfunction , 2005, Circulation.

[276]  R. Holubkov,et al.  Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[277]  H. Inoko,et al.  The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. , 2005, Tissue antigens.

[278]  H. Fechner,et al.  Genome–environment interactions in the molecular pathogenesis of dilated cardiomyopathy , 2005, Journal of Molecular Medicine.

[279]  S. Lipsitz,et al.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[280]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[281]  R. Hershberger,et al.  Clinical and genetic issues in familial dilated cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[282]  M. Komajda,et al.  Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. , 2005, European heart journal.

[283]  C. Tschöpe,et al.  High Prevalence of Cardiac Parvovirus B19 Infection in Patients With Isolated Left Ventricular Diastolic Dysfunction , 2005, Circulation.

[284]  K. Broman,et al.  Two Autoimmune Diabetes Loci Influencing T Cell Apoptosis Control Susceptibility to Experimental Autoimmune Myocarditis1 , 2005, The Journal of Immunology.

[285]  Jeffrey L. Anderson,et al.  Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. , 2005, JAMA.

[286]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[287]  Akshay S. Desai,et al.  Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials , 2004 .

[288]  N. Rose,et al.  Interferon- Protects against Chronic Viral Myocarditis by Reducing Mast Cell Degranulation, Fibrosis, and the Profibrotic Cytokines Transforming Growth Factor- 1, Interleukin-1 , and Interleukin-4 in the Heart , 2004 .

[289]  L. Mestroni,et al.  SCN5A Mutation Associated With Dilated Cardiomyopathy, Conduction Disorder, and Arrhythmia , 2004, Circulation.

[290]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[291]  Martin J. Lohse,et al.  Direct evidence for a β1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy , 2004 .

[292]  E. McNally,et al.  The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. , 2004, Circulation research.

[293]  Udo Sechtem,et al.  Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology , 2004, Circulation.

[294]  N. Rose,et al.  Mast Cells and Innate Cytokines are Associated with Susceptibility to Autoimmune Heart Disease Following Coxsackievirus B3 Infection , 2004, Autoimmunity.

[295]  J. Mogensen,et al.  Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy , 2004, The Lancet.

[296]  M. Isobe,et al.  Cardiac sarcoidosis: Diagnostic, prognostic, and therapeutic considerations , 1996, Cardiovascular Drugs and Therapy.

[297]  H. Hansson,et al.  Regenerating endothelial cells express insulin-like growth factor-I immunoreactivity after arterial injury , 1987, Cell and Tissue Research.

[298]  N. Rose,et al.  Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. , 2004, The American journal of pathology.

[299]  G. Valle,et al.  Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. , 2003, Journal of the American College of Cardiology.

[300]  Yoshimasa Tanaka,et al.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice , 2003, Nature Medicine.

[301]  Kunimasa Suzuki,et al.  Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAβ knockout NOD mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[302]  G. Thiene,et al.  Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. , 2003, Cardiovascular research.

[303]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[304]  H. Schultheiss,et al.  Interferon- (cid:1) Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction , 2003 .

[305]  P. Stenson,et al.  Human Gene Mutation Database (HGMD®): 2003 update , 2003, Human mutation.

[306]  R. Mobini,et al.  Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. , 2003, Journal of autoimmunity.

[307]  F. Morady,et al.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. , 2003, Journal of the American College of Cardiology.

[308]  M. Iwase,et al.  Narrowing of the left ventricular cavity associated with transient ventricular wall thickening reduces stroke volume in patients with acute myocarditis. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[309]  John B Carlin,et al.  The epidemiology of childhood cardiomyopathy in Australia. , 2003, The New England journal of medicine.

[310]  E John Orav,et al.  The incidence of pediatric cardiomyopathy in two regions of the United States. , 2003, The New England journal of medicine.

[311]  L. Mestroni,et al.  Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. , 2003, Journal of the American College of Cardiology.

[312]  Ulrike Mende,et al.  Dilated Cardiomyopathy and Heart Failure Caused by a Mutation in Phospholamban , 2003, Science.

[313]  G. Thiene,et al.  Immunosuppressive Therapy for Active Lymphocytic Myocarditis: Virological and Immunologic Profile of Responders Versus Nonresponders , 2003, Circulation.

[314]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[315]  A. Matsumori.  Cardiomyopathies and heart failure : biomolecular, infectious, and immune mechanisms , 2003 .

[316]  A. Matsumori.  Cardiomyopathies and Heart Failure , 2003, Developments in Cardiovascular Medicine.

[317]  Richard T. Lee,et al.  Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction , 2002, Circulation.

[318]  Milton Packer,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[319]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[320]  Akshay S. Desai,et al.  Cardiomyopathies , 2002, Journal of the Neurological Sciences.

[321]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[322]  M. Piano.  Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. , 2002, Chest.

[323]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[324]  M. Davies,et al.  Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[325]  L. Saxon,et al.  Arrhythmias associated with dilated cardiomyopathy. , 2002, Cardiac electrophysiology review.

[326]  M. Keating,et al.  Metavinculin Mutations Alter Actin Interaction in Dilated Cardiomyopathy , 2002, Circulation.

[327]  John Atherton,et al.  Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy , 2002, Nature Genetics.

[328]  M. Di Franco,et al.  Evaluation of myocardial involvement in systemic lupus erythematosus by signal-averaged electrocardiography and echocardiography , 2001, Acta cardiologica.

[329]  D. Cannom,et al.  Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: Differences in presentation and outcome in the AVID registry. , 2001, American heart journal.

[330]  Romuald Wojnicz,et al.  Randomized, Placebo-Controlled Study for Immunosuppressive Treatment of Inflammatory Dilated Cardiomyopathy: Two-Year Follow-Up Results , 2001, Circulation.

[331]  F. Whitby,et al.  Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. , 2001, Journal of molecular and cellular cardiology.

[332]  D. Haussler,et al.  A physical map of the human genome , 2001, Nature.

[333]  Josef M. Penninger,et al.  CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling , 2001, Nature.

[334]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[335]  S. Solomon,et al.  Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. , 2001, The New England journal of medicine.

[336]  M. Kamisago.  Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy , 2000 .

[337]  G. Berry,et al.  Giant cell myocarditis as a manifestation of drug hypersensitivity. , 2000, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[338]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[339]  M Pohl,et al.  Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. , 2000, Journal of the American College of Cardiology.

[340]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[341]  T. Mak,et al.  The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease , 2000, Nature Medicine.

[342]  M. Dalakas,et al.  Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. , 2000, The New England journal of medicine.

[343]  B. Strauer,et al.  Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. , 2000, Journal of the American College of Cardiology.

[344]  J. Seidman,et al.  Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. , 1999, The New England journal of medicine.

[345]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[346]  L. Mestroni,et al.  Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. , 1999, Journal of the American College of Cardiology.

[347]  P. Burch,et al.  Desmin mutation responsible for idiopathic dilated cardiomyopathy. , 1999, Circulation.

[348]  L. Mestroni,et al.  Clinical StudiesFamilial dilated cardiomyopathy: Evidence for genetic and phenotypic heterogeneity☆ , 1999 .

[349]  L. Mestroni,et al.  Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. , 1999, Journal of the American College of Cardiology.

[350]  J. Towbin,et al.  Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. , 1999, Circulation.

[351]  B. Gersh,et al.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[352]  R. Kandolf,et al.  Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. , 1999, Circulation.

[353]  P. Stolley.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[354]  W. Irving,et al.  Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. , 1998, The Journal of infectious diseases.

[355]  O. Simell,et al.  Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. , 1997, American journal of epidemiology.

[356]  G. Gerken,et al.  MHC class II genes influence the susceptibility to chronic active hepatitis C. , 1997, Journal of hepatology.

[357]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[358]  G. Danieli,et al.  Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. , 1996, Circulation.

[359]  S. di Somma,et al.  Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. , 1996, JAMA.

[360]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[361]  H. Schultheiss,et al.  Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. , 1996, Heart.

[362]  R. Melchert,et al.  Cardiovascular effects of androgenic-anabolic steroids. , 1995, Medicine and science in sports and exercise.

[363]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[364]  B. McManus,et al.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. , 1995, The New England journal of medicine.

[365]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[366]  S. Yusuf,et al.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.

[367]  R. Myerburg,et al.  Cardiac complications of cocaine abuse , 1995, Clinical cardiology.

[368]  H. Schultheiss,et al.  Chronic inflammation in the myocardium of patients with clinically suspected dilated cardiomyopathy. , 1994, Journal of cardiac failure.

[369]  L. Mestroni,et al.  Evidence from family studies for autoimmunity in dilated cardiomyopathy , 1994, The Lancet.

[370]  M. Kodama,et al.  Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. , 1994, Circulation research.

[371]  V. Fuster,et al.  Idiopathic dilated cardiomyopathy. , 1994, The New England journal of medicine.

[372]  B. Gersh,et al.  Black-white differences in mortality in idiopathic dilated cardiomyopathy: the Washington, DC, dilated cardiomyopathy study. , 1994, Journal of the National Medical Association.

[373]  B. Strauer,et al.  Methylprednisolone in chronic myocarditis. , 1994, Postgraduate medical journal.

[374]  W. Stevenson,et al.  Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1993, The American journal of cardiology.

[375]  G. Vetrovec,et al.  Frequency of coronary artery disease and left ventricle dysfunction in cocaine users. , 1992, The American journal of cardiology.

[376]  W. Mckenna,et al.  Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. , 1992, Circulation.

[377]  E. Arbustini,et al.  Search for Coxsackievirus B3 RNA in idiopathic dilated cardiomyopathy using gene amplification by polymerase chain reaction. , 1992, The American journal of cardiology.

[378]  M A House,et al.  Cardiovascular effects of cocaine. , 1992, The Journal of cardiovascular nursing.

[379]  M. Ferraz,et al.  Symptomatic cardiac involvement in juvenile rheumatoid arthritis. , 1992, International journal of cardiology.

[380]  J. Deckers,et al.  Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. , 1992, Journal of the American College of Cardiology.

[381]  P. Allen,et al.  Myosin-induced acute myocarditis is a T cell-mediated disease. , 1991, Journal of immunology.

[382]  B. Strauer,et al.  The Ca-channel as cardiac autoantigen. , 1991, European heart journal.

[383]  N. Bowles,et al.  Molecular probes for detection of persisting enterovirus infection of human heart and their prognostic value. , 1991, European heart journal.

[384]  K. Caidahl,et al.  Non-invasive assessment of systolic left ventricular function in systemic sclerosis. , 1991, European heart journal.

[385]  E. Bonifacio,et al.  Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. , 1990, Journal of the American College of Cardiology.

[386]  P. Poole‐Wilson.  Idiopathic dilated cardiomyopathy. , 1990, BMJ.

[387]  H. Schultheiss,et al.  Antibodies to ADP-ATP carrier--an autoantigen in myocarditis and dilated cardiomyopathy--impair cardiac function. , 1990, Circulation.

[388]  J E Parrillo,et al.  A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. , 1989, The New England journal of medicine.

[389]  A. J. Hauck,et al.  Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. , 1989, Mayo Clinic proceedings.

[390]  L. Melton,et al.  Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. , 1989, Circulation.

[391]  H. Schultheiss,et al.  Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. , 1989, American heart journal.

[392]  N. B. Olivier,et al.  Heart failure depresses endothelium-dependent responses in canine femoral artery. , 1989, The American journal of physiology.

[393]  R. D. Latham,et al.  Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. , 1989, American heart journal.

[394]  R. Estruch,et al.  The effects of alcoholism on skeletal and cardiac muscle. , 1989, The New England journal of medicine.

[395]  H. Schultheiss,et al.  Antibodies to the ADP/ATP carrier, an autoantigen in myocarditis and dilated cardiomyopathy, penetrate into myocardial cells and disturb energy metabolism in vivo. , 1989, Circulation research.

[396]  E. Nabel,et al.  Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. , 1989, Circulation.

[397]  R. Shabetai.  Endomyocardial biopsy. , 1989, Giornale italiano di cardiologia.

[398]  I. Goldenberg,et al.  Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. , 1989, Circulation research.

[399]  E. Sonnenblick,et al.  Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. , 1988, Journal of the American College of Cardiology.

[400]  M. Morad,et al.  Antibody-mediated enhancement of calcium permeability in cardiac myocytes , 1988, The Journal of experimental medicine.

[401]  G. Harsh,et al.  Transcriptional regulation of the A and B chain genes of platelet-derived growth factor in microvascular endothelial cells. , 1988, The Journal of biological chemistry.

[402]  R. Virmani,et al.  Cardiovascular effects of cocaine: an autopsy study of 40 patients. , 1988, American heart journal.

[403]  E. Nabel,et al.  Responses of coronary arteries of cardiac transplant patients to acetylcholine. , 1988, The Journal of clinical investigation.

[404]  K. Beisel,et al.  Cardiac myosin induces myocarditis in genetically predisposed mice. , 1987, Journal of immunology.

[405]  J. Parrillo,et al.  Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest pain. , 1987, Journal of the American College of Cardiology.

[406]  U. Förstermann,et al.  Endothelium-derived relaxing factor is likely to modulate the tone of resistance arteries in rabbit hindlimb in vivo. , 1987, The Journal of pharmacology and experimental therapeutics.

[407]  P. Hofschneider,et al.  In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[408]  H R Figulla,et al.  Inhomogenous capillary flow and its prevention by verapamil and hydralazine in the cardiomyopathic Syrian hamster. , 1987, Circulation.

[409]  J. Scheuer,et al.  Effects of gonadectomy and hormonal replacement on rat hearts. , 1987, Circulation research.

[410]  M. Billingham.  Acute myocarditis: a diagnostic dilemma. , 1987, British heart journal.

[411]  M. Matsuda,et al.  Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. , 1987, Circulation.

[412]  D. Stewart,et al.  Reversal of acetylcholine-induced coronary resistance vessel dilation by hemoglobin. , 1987, European journal of pharmacology.

[413]  W. Edwards,et al.  Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. , 1987, Circulation.

[414]  R. Furchgott,et al.  Evidence for endothelium-dependent vasodilation of resistance vessels by acetylcholine. , 1987, Blood vessels.

[415]  W. Edwards,et al.  Myocarditis. A histopathologic definition and classification. , 1987, The American journal of cardiovascular pathology.

[416]  M. Marcus,et al.  Alterations in the coronary circulation in hypertrophied ventricles. , 1987, Circulation.

[417]  C. Heldin,et al.  Cultured human endothelial cells express platelet-derived growth factor A chain. , 1987, The American journal of pathology.

[418]  C. Hartley,et al.  Subselective measurement of coronary blood flow velocity using a steerable Doppler catheter. , 1986, Journal of the American College of Cardiology.

[419]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[420]  N. Bowles,et al.  DETECTION OF COXSACKIE-B-VIRUS-SPECIFIC RNA SEQUENCES IN MYOCARDIAL BIOPSY SAMPLES FROM PATIENTS WITH MYOCARDITIS AND DILATED CARDIOMYOPATHY , 1986, The Lancet.

[421]  R. Geha,et al.  Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. , 1986, The Journal of clinical investigation.

[422]  L. Boxt,et al.  Selective coronary angiography using a power injector. , 1986, AJR. American journal of roentgenology.

[423]  M. Klagsbrun,et al.  Purification and characterization of heparin-binding endothelial cell growth factors. , 1986, The Journal of biological chemistry.

[424]  C. Steenbergen,et al.  Detection of lymphocytes in endomyocardium using immunohistochemical techniques. Relevance to evaluation of endomyocardial biopsies in suspected cases of lymphocytic myocarditis , 1986 .

[425]  J. Mcanulty,et al.  Lack of objective improvement in ventricular systolic function in patients with myocarditis treated with azathioprine and prednisone. , 1985, Journal of the American College of Cardiology.

[426]  H. Friedman,et al.  Viral infection of vascular endothelial cells alters production of colony-stimulating activity. , 1985, The Journal of clinical investigation.

[427]  H. Friedman,et al.  Herpes simplex virus type 1 infection of endothelium reduces collagen and fibronectin synthesis. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[428]  P. Hofschneider,et al.  Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[429]  T. Feldman,et al.  Adverse cardiac effects of acute alcohol ingestion in young adults. , 1985, Annals of internal medicine.

[430]  E. Olsen.  The problem of viral heart disease. How often do we miss it? , 1985, Postgraduate medical journal.

[431]  D. Baim,et al.  Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. , 1985, Circulation.

[432]  M. Peach,et al.  Endothelium‐Derived Vascular Relaxing Factor , 1985, Hypertension.

[433]  F. Murad,et al.  Effects of Na+,K+-pump inhibitors and membrane depolarizing agents on acetylcholine-induced endothelium-dependent relaxation and cyclic GMP accumulation in rat aorta. , 1985, European journal of pharmacology.

[434]  A. Nitenberg,et al.  Multifactorial determinants of reduced coronary flow reserve after dipyridamole in dilated cardiomyopathy. , 1985, The American journal of cardiology.

[435]  E. Sonnenblick,et al.  Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy. , 1985, The American journal of cardiology.

[436]  J. T. Shepherd,et al.  Vasopressin induces endothelium-dependent relaxations of cerebral and coronary, but not of systemic arteries. , 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[437]  D. Pennington,et al.  High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy. , 1984, Journal of the American College of Cardiology.

[438]  J. Angus,et al.  Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin , 1983, Nature.

[439]  W. Kübler,et al.  Coronary dilatory capacity in idiopathic dilated cardiomyopathy: analysis of 16 patients. , 1983, The American journal of cardiology.

[440]  K. Gould,et al.  AUTOMATED EVALUATION OF VESSEL DIAMETER FROM ARTERIOGRAMS. , 1983 .

[441]  E. Sonnenblick,et al.  Microvascular Spasm in the Cardiomyopathic Syrian Hamster: A Preventable Cause of Focal Myocardial Necrosis , 1982, Circulation.

[442]  C. Henschke,et al.  Pathophysiology of Chest Pain in Patients with Cardiomyopathies and Normal Coronary Arteries , 1982, Circulation.

[443]  H. Friedman,et al.  Virus infection of endothelial cells. , 1981, The Journal of infectious diseases.

[444]  H. Friedman,et al.  Virus infection of endothelial cells increases granulocyte adherence. , 1980, The Journal of clinical investigation.

[445]  J. Mason,et al.  Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. , 1980, The American journal of cardiology.

[446]  G. Hutchins,et al.  Cardiac Sarcoid: A Clinicopathologic Study of 84 Unselected Patients with Systemic Sarcoidosis , 1978, Circulation.

[447]  W. Roberts,et al.  Myocardial biopsy: a useful diagnostic procedure or only a research tool? , 1978, The American journal of cardiology.

[448]  L. Johnson,et al.  Myocardial Blood Flow in Congestive and Hypertrophic Cardiomyopathy: Relationship to Peak Wall Stress and Mean Velocity of Circumferential Fiber Shortening , 1976, Circulation.

[449]  L. Horwitz,et al.  Effect of Isoproterenol on Coronary Blood Flow in Primary Myocardial Disease , 1974, Circulation.

[450]  H. Mösslacher.  [Alcoholic cardiomyopathy]. , 1973, Wiener klinische Wochenschrift. Supplementum.

[451]  H. Swan,et al.  Measurement of Coronary Sinus Blood Flow by Continuous Thermodilution in Man , 1971, Circulation.

[452]  E. Arbustini,et al.  Cardiac Phenotypes in Hereditary Muscle Disorders , 2022 .